+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Neurodegenerative Disease Market - Growth, Trends, and Forecasts 2017 - 2022

  • ID: 4388587
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
The global neurodegenerative disease market accounted for USD XX billion in 2016 and is expected to reach USD XX billion by 2021, growing at a CAGR of XX% during the forecast period.

Neurodegenerative disorders can be genetic, however, their exact cause is unknown. They can arise due to the inability of mitochondria to function properly or because of the deposition of toxic proteins in the brain. The term ‘neurodegeneration’ involves a few diseases under its broad definition and the patients often show symptoms that are interrelated to other diseases under the same broad term. The current market has no curative therapies and thus, available medications can only provide symptomatic relief.

Drivers and Restraints

The prevalence of neurological disorders has been increasing at a constant pace. The increasing awareness among the people about mental disorders and continuous R&D from major market players to find new and effective therapies for treating such disorders are the major market drivers during the period of the forecast. New types of drugs are expected to be launched in the next few years. The existing drugs are to face patent expiries and thus, new players can enter the market.

The market, however, is set to face obstacles due to the complexity of the disorders as well as the fact that the cause of these disorders is unknown most of the times, resulting in poor results for R&D activities. The currently available medications for such diseases and disorders are only successful in providing symptomatic relief. The market, hence, has a high potential for growth and should be tapped at the earliest.

Global Neurodegenerative Disease Market Segmentation

The global neurodegenerative disease market is segmented by the type of indication into Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, and Huntington Disease. Out of these, Alzheimer’s disease is the most prevalent, followed by Parkinson’s disease. The drugs used to provide symptomatic relief are broadly classified into N-methyl-D-aspartate receptor antagonists, selective serotonin reuptake inhibitor, and dopamine inhibitors.

Geographically, the market has been segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. Asia-Pacific is expected to record the highest growth due to its large population base.

Key Players

Some of the largest players in the market are:

Key Deliverables:

Market analysis for the neurodegenerative disease market, with region-specific assessments and competition analysis.

Market definition along with the identification of key drivers, restraints, opportunities, and challenges.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.

Identification and analysis of the macro and micro factors that affect the global neurodegenerative disease market.

Insights of the market in the regions that have the highest potential for growth and to also identify the markets that are still untapped.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 Review and Forecast Period Years
1.4 General Study Assumptions
1.5 Report Description
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Study Timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Porter’s Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Buyers
5.2.3 Degree of Competition
5.2.4 Threat of Substitution
5.2.5 Threat of New Entrants
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Awareness About Mental Disorders
6.1.2 Increased Prevalence of Neurological Disorders
6.1.3 R&D Activities from Key Market Players
6.1.4 New Drug Launches
6.1.5 Patent Expiries Leading to New Entrants in Market
6.2 Market Restraints
6.2.1 Disease Complexity
6.2.2 Inability to Zero Down on Reason of Occurrence During R&D
6.3 Market Opportunities
6.3.1 Failure of Current Medications in Curing the Disorders
6.4 Key Challenges
6.4.1 Some of the Disorders are Very Rare
7. Global Neurodegenerative Disease Market -Segmentation
7.1 Based on Indication Type
7.1.1 Parkinson’s Disease
7.1.2 Amyotrophic Lateral Sclerosis
7.1.3 Alzheimer’s Disease
7.1.4 Huntington Disease
7.1.5 Others
7.2 Based on Drug Type
7.2.1 NMDA
7.2.2 SSRI
7.2.3 Dopamine Inhibitors
7.2.4 Others
8. Global Neurodegenerative Disease Market by Geography - Regional Share and forecasts
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Italy
8.2.5 Spain & Portugal
8.2.6 Scandinavia
8.2.7 Benelux
8.2.8 Rest of Europe
8.3 Asia-Pacific
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East & Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of Middle East & Africa
8.5 Latin America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of Latin America
9. Competitive Landscape
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
10. Company Profiles
10.1 Novartis
10.2 Pfizer
10.3 Merck Serono
10.4 Biogen Idec
10.5 TEVA Pharmaceuticals Industries
10.6 UCB
10.7 Bayer Schering
10.8 Boehringer Ingelheim
10.9 Sanofi S.A.
10.10 GlaxoSmithKline
10.11 Others
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3